CHORIOGONADOTROPIN ALFA

Brand name:

• Ovidrel®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Merck Healthcare Pty Ltd

Condition/indication:
(therapeutic use)

• Assisted reproductive technology

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (–)

Comment:

There is no Public Summary Document for this item

Other PBAC consideration:

--

Submission received for::

September 2021 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 03/09/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

27/10/2021

Lodgement of required documentation:

09/11/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 03/05/2023

Status:

Finalised

Government processes:

Commenced on 10/05/2023

Medicine listed on the PBS:

01/07/2023 (see PBS schedule)